Fig. 2

Kaplan-Meier analyses of progression free survival of mCRPC patients treated with Enzalutamide who do not show a sufficientent initial PSA decline ≥ 50%

a) with and without LDH normalization

b) with and without ALP rising at 12 weeks independent of LDH dynamics, and

c) with and without ALP rising at 12 weeks, without LDH normalizastion